Authors
Loading...
Observational analysis shows that targeting BRD9 reduces resistance in AML cells with KMT2A rearrangements, suggesting a new therapeutic approach.
Daniela V. Wenge (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: